Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using stated preference and revealed preference modeling to evaluate prescribing decisions.

Tami L Mark1, Joffre Swait

  • 1Outcomes Research and Econometrics, Medstat, Washington, DC 20008, USA. tami.mark@medstat.com

Health Economics
|June 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can the GAD-7 be used to create valid, reliable, feasible and actionable outcome-focused paediatric anxiety quality measures for use across specialty and paediatric treatment settings?

BMJ open·2026
Same author

Cascade of Care for Opioid Use Disorder Among Medicaid Beneficiaries.

JAMA network open·2026
Same author

US National Spending On Mental Health And Substance Use Disorder Treatment Driven By Case Growth, 2000-21.

Health affairs (Project Hope)·2026
Same author

Opioid Treatment Programs' Medicaid Patient Retention Rates.

JAMA network open·2026
Same author

Suicide Deaths Among Medicaid Beneficiaries.

Psychiatric services (Washington, D.C.)·2025
Same author

Retention among Medicaid beneficiaries in opioid treatment programs in California.

Journal of substance use and addiction treatment·2025
Same journal

Healthcare Costs Following Medical Gender-Affirmation: Evidence From Whole-of-Population Australian Administrative Data.

Health economics·2026
Same journal

Lead in Drinking Water and Child Health: Evidence From Jackson, Mississippi.

Health economics·2026
Same journal

Health on the Move: The Impact of Poverty Alleviation Relocation on Healthcare Utilization in China.

Health economics·2026
Same journal

The Effects of Compulsory Licensing: A Case Study of HIV Drugs.

Health economics·2026
Same journal

Beyond Tobacco Prevention: The Effects of Tobacco 21 Laws on Young Adults' Body Weight.

Health economics·2026
Same journal

Assessing the Estimands and Estimates of Hospitalization Rates in Health Economics and Clinical Medicine.

Health economics·2026
See all related articles

This study integrates stated preference data with revealed preference data to understand physician prescribing habits for alcoholism medications. Combining these methods offers a more comprehensive view of medication choice factors.

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Behavioral Economics

Background:

  • Stated preference (SP) analyses are increasingly used for healthcare product evaluation.
  • Revealed preference (RP) data offers insights into actual choices, while SP data captures hypothetical choices.
  • Understanding physician prescribing behavior for alcoholism medications is crucial for effective treatment.

Purpose of the Study:

  • To demonstrate how revealed preference data can be enhanced with stated preference data.
  • To highlight the complementary advantages of both revealed and stated preference data.
  • To analyze determinants of physicians' prescribing rates for alcoholism medications.

Main Methods:

  • Applied stated and revealed preference techniques to physician prescribing data for alcoholism medications.

Related Experiment Videos

  • Analyzed relationships between physician perceptions of medication attributes and prescribing rates.
  • Examined physician decisions for hypothetical medications with varied attributes (efficacy, side effects, price, etc.).
  • Conducted joint estimation using combined stated and revealed preference data.

    • Main Results:

    • Joint estimation indicated that parameters from revealed and stated preference data are equivalent, up to scale.
    • Stated preference data enabled estimation of parameters for attributes not observed or varying in the marketplace.
    • Combined analyses revealed how stated preference data addresses attribute collinearity issues present in actual markets.

    Conclusions:

    • Integrating stated and revealed preference data provides a robust framework for analyzing healthcare choices.
    • Stated preference data is valuable for estimating the impact of unobserved or invariant attributes on prescribing behavior.
    • This combined approach enhances the understanding of factors influencing physician medication choices in complex markets.